ALP Bio AG has successfully raised €1.9 million in pre-seed funding to enhance its innovative immune organoid AI platform aimed at addressing immunogenicity risks in drug development.
The funding round, led by Munich-based 42CAP with contributions from Venture Kick and angel investors, marks a significant step for the Swiss biotech startup founded in 2025. ALP Bio's platform uniquely integrates human tonsil organoid biology with generative AI to identify and mitigate the formation of anti-drug antibodies (ADAs) early in the drug development process. This proactive approach aims to reduce the costly late-stage failures that often plague biologics due to immune responses against therapeutic proteins.
Immunogenicity remains a critical challenge in the industry, frequently leading to clinical trial failures when immune systems react adversely to treatments. By using organoid technology to simulate immune responses in vitro, ALP Bio hopes to produce actionable insights long before clinical trials commence. The pre-seed funding will primarily be allocated to expanding lab capabilities, initiating collaborations with pharmaceutical partners, and strengthening the team in both Switzerland and the United States.
As the global market for preclinical antibody development is set to grow significantly, ALP Bio's focus on immunogenicity could position it advantageously against competitors. Unlike others that address immunogenicity as a secondary concern, ALP Bio prioritizes it, potentially transforming how the industry approaches antibody design and development. This unique positioning, combined with a strategic blend of biological and computational methodologies, could lead to more efficient and successful drug development processes.